[go: up one dir, main page]

JP2011503013A - 安全なｎｍｄａ受容体拮抗薬を同定する方法 - Google Patents

安全なｎｍｄａ受容体拮抗薬を同定する方法 Download PDF

Info

Publication number
JP2011503013A
JP2011503013A JP2010532343A JP2010532343A JP2011503013A JP 2011503013 A JP2011503013 A JP 2011503013A JP 2010532343 A JP2010532343 A JP 2010532343A JP 2010532343 A JP2010532343 A JP 2010532343A JP 2011503013 A JP2011503013 A JP 2011503013A
Authority
JP
Japan
Prior art keywords
compound
potency
nmda receptor
pain
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010532343A
Other languages
English (en)
Japanese (ja)
Inventor
デイングルデイーン，レイモンド・ジエイ
トレイネリス，ステイーブン・エフ
リオツタ，デニス・シー
Original Assignee
エモリー・ユニバーシテイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エモリー・ユニバーシテイ filed Critical エモリー・ユニバーシテイ
Publication of JP2011503013A publication Critical patent/JP2011503013A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2857—Seizure disorders; Epilepsy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2010532343A 2007-11-06 2008-11-06 安全なｎｍｄａ受容体拮抗薬を同定する方法 Pending JP2011503013A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98592207P 2007-11-06 2007-11-06
US98592407P 2007-11-06 2007-11-06
PCT/US2008/082660 WO2009061935A2 (en) 2007-11-06 2008-11-06 Methods of identifying safe nmda receptor antagonists

Publications (1)

Publication Number Publication Date
JP2011503013A true JP2011503013A (ja) 2011-01-27

Family

ID=40626437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010532343A Pending JP2011503013A (ja) 2007-11-06 2008-11-06 安全なｎｍｄａ受容体拮抗薬を同定する方法

Country Status (12)

Country Link
EP (1) EP2212694A4 (pt)
JP (1) JP2011503013A (pt)
KR (1) KR20100100858A (pt)
CN (1) CN101918832A (pt)
AU (1) AU2008323877A1 (pt)
BR (1) BRPI0820406A2 (pt)
CA (1) CA2704475A1 (pt)
EA (1) EA201070571A1 (pt)
IL (1) IL205432A0 (pt)
MX (1) MX2010004971A (pt)
WO (1) WO2009061935A2 (pt)
ZA (1) ZA201003724B (pt)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012169517A1 (ja) * 2011-06-08 2012-12-13 アステラス製薬株式会社 慢性疼痛モデル動物における自発痛行動自動測定法
JP2018521007A (ja) * 2015-05-22 2018-08-02 ヴィスタゲン セラピューティクス、インコーポレイテッド Ｌ−４−クロロキヌレニンの治療的使用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3383429B1 (en) 2015-11-30 2020-10-14 INSERM - Institut National de la Santé et de la Recherche Médicale Nmdar antagonists for the treatment of tumor angiogenesis
CN111960514A (zh) * 2020-08-28 2020-11-20 浙江浙能技术研究院有限公司 一种用于脱硫废水浓缩的电渗析智能控制系统及方法
CN118019541A (zh) 2021-09-02 2024-05-10 埃默里大学 在酸性pH下具有增强的效力的N-甲基-D-天冬氨酸受体的GLUN2B-亚基选择性拮抗剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
WO2006023957A1 (en) * 2004-08-23 2006-03-02 Emory University Improved selection of-ph dependent compounds for in vivo therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030063765A (ko) * 2002-01-24 2003-07-31 엘지전자 주식회사 광픽업용 대물렌즈
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
WO2005061536A1 (en) * 2003-12-16 2005-07-07 Aventis Pharmaceuticals Inc. Secreted neural apoptosis inhibiting proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
WO2006023957A1 (en) * 2004-08-23 2006-03-02 Emory University Improved selection of-ph dependent compounds for in vivo therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6011030913; Ｍｏｔｔ　Ｄ．Ｄ．　ｅｔ　ａｌ．: 'Ｐｈｅｎｙｌｅｔｈａｎｏｌａｍｉｎｅｓ　ｉｎｈｉｂｉｔ　ＮＭＤＡ　ｒｅｃｅｐｔｏｒｓ　ｂｙ　ｅｎｈａｎｃｉｎｇ　ｐｒｏｔｏｎ　ｉｎｈｉｂｉｔｉｏｎ．' Ｎａｔ．Ｎｅｕｒｏｓｃｉ． Ｖｏｌ．１（８）, 1998, ｐ．６５９-６７ *
JPN6013024644; Ｊ　Ｃｅｒｅｂ　Ｂｌｏｏｄ　Ｆｌｏｗ　Ｍｅｔａｂ．，　Ｖｏｌ．１１，　ｐ．７８６-７９３　（１９９１） *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012169517A1 (ja) * 2011-06-08 2012-12-13 アステラス製薬株式会社 慢性疼痛モデル動物における自発痛行動自動測定法
JP2018521007A (ja) * 2015-05-22 2018-08-02 ヴィスタゲン セラピューティクス、インコーポレイテッド Ｌ−４−クロロキヌレニンの治療的使用

Also Published As

Publication number Publication date
IL205432A0 (en) 2010-12-30
MX2010004971A (es) 2010-07-28
EP2212694A2 (en) 2010-08-04
CN101918832A (zh) 2010-12-15
AU2008323877A1 (en) 2009-05-14
EP2212694A4 (en) 2011-10-12
BRPI0820406A2 (pt) 2015-05-19
ZA201003724B (en) 2013-10-30
WO2009061935A3 (en) 2009-08-20
CA2704475A1 (en) 2009-05-14
KR20100100858A (ko) 2010-09-15
WO2009061935A2 (en) 2009-05-14
EA201070571A1 (ru) 2010-12-30

Similar Documents

Publication Publication Date Title
JP5015779B2 (ja) インビボ治療のためのｐＨ依存性化合物の改良選択法
CN113164589A (zh) 用于调节单核细胞和巨噬细胞发炎表型的组合物和方法以及其免疫疗法用途
JP2011503013A (ja) 安全なｎｍｄａ受容体拮抗薬を同定する方法
US20110081428A1 (en) Use of thioflavin-like compounds to increase life span and/or health span
KR20160009667A (ko) 염증의 예방 및 치료를 위한 크리오피린 억제제
Shimizu et al. Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) mediates periarticular bone loss, but not joint destruction, in murine antigen-induced arthritis
JP2021534101A (ja) Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用
EP3643697A1 (en) Treatment method, compounds, and method of increasing trpv2 activity
CN106660950A (zh) Cxcr2拮抗剂用于预防和/或治疗化疗诱导的周围神经病变(cipn)的用途
CA3005375C (en) Pharmaceutical compositions for treating pain
EP3220908B1 (en) Compositions and methods for treating endometriosis
KR20110084533A (ko) 암의 치료를 위한 엔자스타우린
EP3719021B1 (en) Inhibitors of adapter associated kinase 1, compositions comprising them, and methods of their use
Lee et al. Soluble receptor for advanced glycation end products inhibits disease progression in autosomal dominant polycystic kidney disease by down‐regulating cell proliferation
US20210353585A1 (en) Methods and compositions for treating laminopathies affecting skeletal or cardiac muscle
US20090291150A1 (en) Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
US20110077283A1 (en) Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
JP2006525784A (ja) 膜貫通型タンパク質ａｍｉｇｏおよびその用途
US20100272648A1 (en) Methods of Identifying Improved NMDA Receptor Antagonists
US20160208266A1 (en) Methods and Means for Treatment of Osteoarthritis
US8816151B2 (en) Stat5b transgenic mice and methods of use thereof
Hayot et al. Morphological and functional recovery from diaphragm injury: an in vivo rat diaphragm injury model
Martin The Contribution of ICAM-1 in Muscle Regeneration after Injury
D’Agati et al. Glycation: Receptor for Advanced Glycation Endproducts and Diabetic Nephropathy
WO2006059637A1 (ja) Ccr8阻害剤を用いる癒着の診断、予防および治療剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130528

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131210